Clinical Trials
15 trialsNCT07284433 2026-04-02
QUADvance
AvenCell Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT04416984 2026-03-04
ALPHA2
Allogene Therapeutics
Phase 1/2 Active not recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05589896 2026-02-24
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Phase 1/2 Recruiting
NCT07157514 2025-09-10
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT03743246 2024-08-15
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Phase 1/2 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT02781467 2020-07-22
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Celularity Incorporated
Phase 1 Terminated
NCT03173417 2019-05-20
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Completed
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT00109031 2014-09-15
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Swedish Orphan Biovitrum
Phase 3 Completed
NCT00315705 2014-04-14
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Sanofi
Phase 1/2 Completed
NCT00281918 2013-09-19
CLL-8
Hoffmann-La Roche
Phase 3 Completed